FOXO TECHNOLOGIES INC. Net Income (Loss) Available to Common Stockholders, Diluted
FOXO TECHNOLOGIES INC. (FOXO) reported Net Income (Loss) Available to Common Stockholders, Diluted of $8.41 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-14
- FOXO TECHNOLOGIES INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was $8.41M.
- FOXO TECHNOLOGIES INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$1.45M.
- FOXO TECHNOLOGIES INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was -$18.39M.
- FOXO TECHNOLOGIES INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$14.14M.
- FOXO TECHNOLOGIES INC. net income (loss) available to common stockholders, diluted for fiscal 2025 was -$34.10M.
- FOXO TECHNOLOGIES INC. net income (loss) available to common stockholders, diluted for fiscal 2024 was -$13.48M.
- FOXO TECHNOLOGIES INC. net income (loss) available to common stockholders, diluted for fiscal 2023 was -$29.83M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $8.41M 10-Q · filed 2026-08-14 | $7.39M 10-Q · filed 2026-08-14 | -$11.42M derived: sum of 3 quarters · filed 2026-08-14 | -$25.57M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2026-03-31 | -$1.45M 10-Q · filed 2026-05-15 | -$19.84M derived: sum of 2 quarters · filed 2026-05-15 | -$33.98M derived: sum of 3 quarters · filed 2026-05-15 | -$34.94M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-12-31 | -$18.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | -$32.53M derived: sum of 2 quarters · filed 2026-04-15 | -$33.48M derived: sum of 3 quarters · filed 2026-08-14 | -$34.10M 10-K · filed 2026-04-15 | |||
| 2025-09-30 | -$14.14M 10-Q · filed 2025-11-10 | -$15.10M derived: sum of 2 quarters · filed 2026-08-14 | -$15.72M 10-Q · filed 2025-11-10 | -$22.70M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-06-30 | -$955.61K 10-Q · filed 2026-08-14 | -$787.09K 10-Q · filed 2025-08-19 | -$2.06M 10-Q · filed 2026-08-14 | -$1.58M 10-Q · filed 2025-08-19 | -$8.56M derived: sum of 3 quarters · filed 2026-08-14 | -$10.59M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | -$788.58K 10-Q · filed 2026-05-15 | -$7.60M derived: sum of 2 quarters · filed 2026-05-15 | -$9.64M derived: sum of 3 quarters · filed 2026-05-15 | -$12.11M derived: sum of 4 quarters · filed 2026-05-15 | |||
| 2024-12-31 | -$6.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | -$8.85M derived: sum of 2 quarters · filed 2026-04-15 | -$11.32M derived: sum of 3 quarters · filed 2026-04-15 | -$13.48M 10-K · filed 2026-04-15 | |||
| 2024-09-30 | -$2.03M 10-Q · filed 2025-11-10 | -$4.51M derived: sum of 2 quarters · filed 2025-11-10 | -$6.67M 10-Q · filed 2025-11-10 | -$10.53M derived: sum of 4 quarters · filed 2025-11-10 | |||
| 2024-06-30 | -$2.47M 10-Q · filed 2025-08-19 | -$4.63M 10-Q · filed 2025-08-19 | -$8.49M derived: sum of 3 quarters · filed 2025-08-19 | -$13.06M derived: sum of 4 quarters · filed 2025-08-19 | |||
| 2024-03-31 | -$2.16M 10-Q/A · filed 2025-08-19 | -$6.02M derived: sum of 2 quarters · filed 2025-08-19 | -$10.59M derived: sum of 3 quarters · filed 2025-08-19 | ||||
| 2023-12-31 | -$3.86M derived: 10-K 12 month − 10-Q/A 9 month · filed 2025-04-15 | -$8.43M derived: sum of 2 quarters · filed 2025-04-15 | -$29.83M 10-K · filed 2025-04-15 | ||||
| 2023-09-30 | -$4.57M 10-Q/A · filed 2024-06-04 | -$3.66M 10-Q · filed 2024-01-19 | -$25.97M 10-Q/A · filed 2024-06-04 | -$25.06M 10-Q · filed 2024-01-19 | |||
| 2022-09-30 | -$41.03M 10-Q/A · filed 2024-06-04 | -$76.93M 10-Q/A · filed 2024-06-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |